Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya
In 1987, an isolated case of fatal Marburg disease was recognized during routine clinical haemorrhagic fever virus surveillance conducted in Kenya. This report describes the isolation and partial characterization of the new Marburg virus (strain Ravn) isolated from this case. The Ravn isolate was indistinguishable from reference Marburg virus strains by cross-neutralization testing. Virus particles and aggregates of Marburg nucleocapsid matrix in Ravn-infected vero cells, were visualized by immunoelectron microscopic techniques, and also in tissues obtained from the patient and from inoculated monkeys. The cell culture isolate produced a haemorrhagic disease typical of Marburg virus infection when inoculated into rhesus monkeys. Disease was characterized by the sudden appearance of fever and anorexia within 4 to 7 days, and death by day 11. Comparison of nucleotide sequences for portions of the glycoprotein genes of Marburg-Ravn were compared with Marburg reference strains Musoki (MUS) and Popp (POP). Nucleotide identity in this alignment between RAV and MUS is 72.3%, RAV and POP is 71%, and MUS and POP is 91.7%. Amino acid identity between RAV and MUS is 72%, RAV and POP is 67%, and MUS and POP is 93%. These data suggest that Ravn is another subtype of Marburg virus, analogous to the emerging picture of a spectrum of Ebola geographic isolates and subtypes.
KeywordsDisseminate Intravascular Coagulation Plaque Form Unit Rift Valley Fever Rift Valley Fever Virus Pyrimethamine Sulfadoxine
Unable to display preview. Download preview PDF.
- 1.Arata AA, Johnson BK (1978) Approaches towards studies of potential reservoirs of viral haemorrhagic fever in Southern Sudan (1977). In: Pattyn SR (ed) Ebola virus hemorrhagic fever. Elsevier/North-Holland Biomedical Press, Amsterdam, pp 191–200Google Scholar
- 2.Centers for Disease Control and Prevention (1995) Update: outbreak of Ebola viral haemorrhagic fever-Zaire, 1995. MMWR 44: 381–382Google Scholar
- 3.Centers for Disease Control (1995) Management of patients with suspected viral haemorrhagic fever. MMWR 44: 475–479Google Scholar
- 7.Feldmann H, Klenk HD, Sanchez A (1993) Molecular biology and evolution of filoviruses. In: Kaaden OR, Eichhorn W, Czerny CP (eds) Unconventional agents and unclassified viruses. Recent advances in biology and epidemiology. Springer, Wien New York, pp 81–100 (Arch Virol [Suppl] 7)Google Scholar
- 10.Hawiger J (1980) Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med 75: 93–108Google Scholar
- 11.Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peters CJ (1996) Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989–1990 U.S. epizootic. In: Schwarz TF, Siegl G (eds) Imported virus infections. Springer, Wien New York, pp 115–134 (Arch Virol [Suppl] 11)Google Scholar
- 12.Jahrling PB (1995) Filoviruses and arenaviruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 6th ed. ASM Press, Washington, pp 1068–1081Google Scholar
- 18.Siegert R (1970) The Marburg virus (vervet monkey agent). Mod Trends Med Virol 32: 204–240Google Scholar
- 19.Simpson DIH, Zlotnbik I, Rutter DA (1968) Vervet monkey disease. Experimental infection of guinea pigs and monkeys with the causative agent. Br J Exp Pathol 69: 458–464Google Scholar
- 21.Triplett DA, Smith C (1982) Routine testing in the coagulation laboratory. In: Triplett DA (ed) Laboratory evaluation of coagulation. American Society of Clinical Pathologists Press, Chicago, pp 27–52Google Scholar